Information Provided By:
Fly News Breaks for September 12, 2019
TOCA
Sep 12, 2019 | 12:45 EDT
Ladenburg analyst Wangzhi Li downgraded Tocagen to Neutral from Buy after the company said the Phase 3 pivotal Toca 5 study for the treatment of recurrent high-grade gliomas missed the primary endpoint of overall survival.
News For TOCA From the Last 2 Days
There are no results for your query TOCA